


Isolation, Structural Assignment, and Total Synthesis of Barmumycin

Adriana Lorente,[†] Daniel Pla,^{†,‡} Librada M. Cañedo,[‡] Fernando Albericio,^{*,†,§,||} and Mercedes Álvarez^{*,†,§,⊥}

[†]Institute for Research in Biomedicine, Barcelona Science Park, University of Barcelona, Baldiri Reixac 10, E-08028 Barcelona, Spain, [‡]Instituto Biomar, S.A. Parque Tecnológico de León-M10.4, E-24009 Armunia, León, Spain, [§]CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Barcelona Science Park, Baldiri Reixac 10, 08028 Barcelona, Spain, ^{||}Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain, and [⊥]Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain. [#]Current address: Memorial Sloan-Kettering Cancer Center, New York, NY 10065. E-mail: plaquerd@mskcc.org

fernando.albericio@irbbarcelona.org; mercedes.alvarez@irbbarcelona.org

Received September 23, 2010



Barmumycin was isolated from an extract of the marine actinomycete *Streptomyces* sp. BOSC-022A and found to be cytotoxic against various human tumor cell lines. On the basis of preliminary one- and two-dimensional ¹H and ¹³C NMR spectra, the natural compound was initially assigned the structure of macrolactone-type compound **1**, which was later prepared by two different routes. However, major spectroscopic differences between isolated barmumycin and **1** led to revision of the proposed structure as *E*-**16**. On the basis of the synthesis of this new compound, and subsequent spectroscopic comparison of it to an authentic sample of barmumycin, the structure of the natural compound was indeed confirmed as that of *E*-**16**.

Introduction

Natural products from terrestrial plants and microorganisms have long been a traditional source of drugs; however, over the past few years, marine organisms have garnered ever-increasing attention as a rich bank of new bioactive compounds.¹ Marine actinomycetes have also proven to be an important source of biologically active compounds.²

Among the marine actinomycetes that our group has studied, those of the genus *Streptomyces* have clearly shown the most pharmacological potential; however, in many bioactive cultures they have yielded only compounds that are already known. During ongoing research efforts to explore the biosynthetic potential of rare marine microorganisms, we isolated two known compounds, pretomaymycin³ and oxotomaymycin⁴ (Figure 1), plus the previously unknown compound barmumycin from

the culture broth of the marine actinomycete *Streptomyces* sp. BOSC-022A, isolated from a tunicate collected off the Scottish coast. Barmumycin and its diacetate show antitumor activity at micromolar concentrations in all 12 cancer cell lines tested (see Table 1 in the Supporting Information). Herein we report the isolation, total synthesis, and structure elucidation of barmumycin.

Results and Discussion

The molecular formula of barmumycin was determined to be C₁₅H₁₉NO₄ by HRMS MALDI-TOF; it gave an (M + H)⁺ ion at *m/z* 278.13840 (calcd *m/z* 278.13869 for C₁₅H₂₀NO₄). Reaction of barmumycin with acetic anhydride and pyridine gave a diacetyl derivative, confirmed by MS, pointing the presence of two OH and/or NH protons (see Figure 2).

¹H NMR shows three groups of protons (see Table 2 in the Supporting Information). The first group is in the aromatic region and contains three protons at 6.90 (d), 7.03 (d), and 7.08 (s) ppm; the chemical shifts indicated a 1,2,4-substituted electron-rich benzene ring. The second group corresponds to a single vinylic proton at 5.34 ppm (m). The third region comprises an upfield CH shift at 4.67 ppm (m); two methyl

(1) Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. *Nat. Rev. Drug Discov.* **2009**, *8*, 69–85.

(2) (a) Olano, C.; Mendez, C.; Salas, J. A. *Mar. Drugs* **2009**, *7*, 210–248.

(b) Bull, A. T.; Stach, J. E. *Trends Microbiol.* **2007**, *15*, 491–499.

(3) Shimizu, K. I.; Kawamoto, I.; Tomita, F.; Morimoto, M.; Fujimoto, K. *J. Antibiot.* **1982**, *35*, 972–978.

(4) Kariyone, K.; Yazawa, I.; Kohsaka, M. *Chem. Pharm. Bull.* **1971**, *19*, 2289–2293.




FIGURE 1. Two known compounds isolated from *Streptomyces* sp. BOSC-022A.




FIGURE 2. Structure of **1** showing ^1H NMR (blue) and ^{13}C NMR (red) chemical shifts (left) and its HMBC and NOE correlations (right).

groups, seen at 3.90 ppm (s) and 1.62 ppm (d); and the signals of three CH_2 at 4.07 (bt), 4.18 (bd), 3.75 (m), 2.29 (m) and 2.71 (m) ppm. On the basis of these data, the MS findings, and further data from one-dimensional and two-dimensional (COSY, HMBC, and NOESY) ^1H and ^{13}C NMR experiments, we initially proposed that the structure of the isolated natural product was that of benzomacrolactone **1**, derived from 5-methoxy-2-aminobenzoic acid with an exocyclic (*E*)-ethylidene and one alcohol function (Figure 2).

Decanolides are chemical entities abundant in terrestrial organisms, though only a few (e.g., modiolides A and B⁵ and xestodecalactones A–C⁶) have been isolated from marine sources. To the best of our knowledge, the aniline moiety within its 10-membered lactone had never been reported in naturally occurring macrocycles.

We sought to synthesize **1** to compare it against an authentic sample of barmumycin in order to assess its structural assignment. Our retrosynthetic analysis of **1** entailed formation of the exocyclic double bond via Wittig reaction; dihydroxylation of a double bond to give the alcohol required for lactonization; and finally, introduction of a functionalized five-carbon chain onto the nitrogen of methyl 2-amino-5-methoxybenzoate (Scheme 1).

The functionalized five-carbon chain on the aniline nitrogen was introduced by two different ways: via reductive amination (Scheme 2) and via *N*-alkylation (Scheme 3).

Homoallylic alcohol **2** was obtained by Barbier reaction of 2,2-dimethoxyacetaldehyde with allyl bromide and indium powder in water (95% yield).⁷

Attempts at direct deprotection of the dimethyl acetal under acidic conditions led to polymerization of **2**;⁸ therefore, the alcohol had to be protected. Acetylation of the alcohol to give compound **3**,⁷ followed by dimethyl acetal deprotection using LiBF_4 in $\text{MeCN}-\text{H}_2\text{O}$,⁹ gave the aldehyde **4** in excellent yield.

Reductive amination of **4** with aniline **5**¹⁰ required special conditions due to the poor nucleophilicity of the aniline (which is deactivated by the methyl ester group in the *ortho* position): thus, reaction of **4**, **5**, phenylsilane, and dibutyltin dichloride under microwave irradiation for short reaction times gave the aminoalkene **6a** in 67% yield.^{11,12} Attempts at protecting the aniline NH in **6a** as a *t*Bu carbamate failed due to its poor reactivity; therefore, **6a** was treated with K_2CO_3 in MeOH to give the deacetylated derivative **6b**. However, all attempts at oxidizing **6b** to its ketone derivative resulted in decomposition of the starting material.¹³ Thus, the aniline had to be protected, but this was not possible in the presence of the unprotected alcohol. Exploiting the lack of reactivity of the aromatic amine toward Boc protection, and using standard conditions, **6b** was converted into its *t*Bu carbonate derivative **6c** in 43% yield.¹⁴ The aniline group of **6c** was then orthogonally protected using $(\text{CF}_3\text{CO})_2\text{O}$ in pyridine to afford the trifluoroacetamide derivative **6d** in quantitative yield. Treatment of **6d** with 10% TFA in CH_2Cl_2 to remove the carbonate gave the free alcohol **6e** in quantitative yield. Compound **6e** was then oxidized with Dess–Martin periodinate (DMP)¹⁵ to yield the ketone **7** in 93% yield. Slow addition of **7** to *N*-methylmorpholine oxide (NMO) and a catalytic amount of OsO_4 in acetone– H_2O to generate the corresponding diol **8** while preventing double-bond isomerization gave **8** in good yield. Diol **8** was further protected by conversion into its 2,2-dimethyl-1,3-dioxolane derivative **9** using 2,2-dimethoxypropane plus pyridinium *p*-toluenesulfonate (PPTS) as catalyst (quantitative yield). Deprotection of the amine in **9** via mild basic hydrolysis gave the free amine **10** in 97% yield.

A faster and better yielding synthesis of **10** (Scheme 3) was done in parallel to the route described above. The first step was dihydroxylation of isobutyl but-3-enoate. The introduction of the bromomethyl residue was planned for a later step. The oxidation conditions described above afforded isobutyl 3,4-dihydroxybutanoate (**11**), which was then further protected as the 2,2-dimethyl-1,3-dioxolane derivative **12**, in excellent overall yield for both steps. The key step, transformation of **12** into the bromoketone **13** using bromomethyl lithium, gave **13** in 49% yield. *N*-Alkylation of **5** with **13** under microwave irradiation gave **10**.

Wittig chemistry was employed to introduce the ethylidene chain. Reaction of **10** with the Wittig ylide derived from ethyltriphenylphosphonium bromide yielded **14** (43%) as a mixture of *Z/E* diastereomers.¹⁶

Z/E-**14** was transformed into **1** in three successive reactions: hydrolysis of the methyl ester, acetonide deprotection under acidic conditions, and macrocyclization. The acid *Z*-**15** was obtained by purification of the *Z/E* mixture of acids by semipreparative HPLC.¹⁷

Racemic *Z*-**1** was obtained in 35% yield by acetal deprotection followed by macrocyclization using EDC·HCl and

(11) Kangasmetsä, J. J.; Johnson, T. *Org. Lett.* **2005**, *7*, 5653–5655.

(12) Other reduction conditions proved unsuccessful. These included $\text{NaBH}(\text{OAc})_3$ in THF at room temperature for 16 h, $\text{NaBH}(\text{OAc})_3$ in $\text{CH}_2\text{Cl}_2/\text{AcOH}$ at room temperature for 5 h, and $\text{NaBH}(\text{OAc})_3$ in toluene at 110 °C for 2 h.

(13) The aniline **5** was isolated from the oxidation degradation mixture. Its formation could be rationalized through hydrolysis of the enamine resulting from enolization of the keto compound.

(14) Under these conditions, methyl 2-(5-allyl-2-oxooxazolidin-3-yl)-5-methoxybenzoate was isolated as a byproduct in 27% yield.

(15) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155–4156.

(16) The *Z/E* stereoisomers were in a ratio of 73:27 (based on NMR signal areas).

(17) The NOESY correlations between $^4\text{CH}_2$ (2.27 and 2.41 ppm) and the vinyl proton (5.58 ppm) confirmed the stereochemistry of (*Z*)-**15** (see NOESY interactions in the Supporting Information).

(5) Tsuda, M.; Mugishima, T.; Komatsu, K.; Sone, T.; Tanaka, M.; Mikami, Y.; Kobayashi, J. *J. Nat. Prod.* **2003**, *66*, 412–415.

(6) Edrada, R. A.; Heubes, M.; Brauers, G.; Wray, V.; Berg, A.; Gräfe, U.; Wohlfarth, M.; Mühlbacher, J.; Schaumann, K.; Sudarsono; Bringmann, G.; Proksch, P. *J. Nat. Prod.* **2002**, *65*, 1598–1604.


(7) Chenevert, R.; Graviil, S.; Bolte, J. *Tetrahedron: Asymmetry* **2005**, *16*, 2081–2086.

(8) The instability of α -hydroxy aldehydes due to their partial isomerization into α -hydroxy ketones has previously been reported; see: Crestia, D.; Guérard, C.; Bolte, J.; Demuyneck, C. *J. Mol. Catal. B: Enzym.* **2001**, *11*, 207–212.


(9) Lipshutz, B. H.; Harvey, D. F. *Synth. Commun.* **1982**, *12*, 267–277.

(10) Theeraladanon, C.; Arisawa, M.; Nishida, A.; Nakagawa, M. *Tetrahedron* **2004**, *60*, 3017–3035.

SCHEME 1. Retrosynthetic Analysis of Compound 1



SCHEME 2. Route A for the Synthesis of 10



solid-supported DMAP in a 5 mM CH_2Cl_2 solution. The ^1H NMR spectrum of *Z*-1 showed two doublets for the CH_3 linked to the double bond (1.42 ppm and 1.45 ppm) and two quadruplets for the vinylic proton (5.51 and 5.53 ppm).¹⁸ These data could be explained by the presence of two highly populated conformations of *Z*-1 at room temperature. Therefore, we studied peak coalescence by ^1H NMR run at different temperatures. Spectra from the initial experiments, run up to 55 °C in CDCl_3 as solvent, exhibited this trend, but coalescence was not reached at this temperature limit. Finally, coalescence was almost reached in $\text{DMSO}-d_6$ as solvent at 145 °C (see Table 4 in the Supporting Information). Moreover, comparison of spectroscopic data for barmumycin with those for *Z*-1 revealed dramatic differences in the chemical shifts (see Tables 2 and 3 in the Supporting Information). This discrepancy, despite the conflicting stereochemistry of the two compounds (*Z*-1 and *E*-barmumycin), led us to pursue a new structural assignment.

Re-evaluation of all possible alternative structures led us to systematic elucidation of *E*-16 as a novel structure for barmumycin (Figure 3). Interestingly, the very close structural resemblance of 16 to the pretomaymycin and oxotomaymycin isolated from the extract (Figure 1) suggests that

(18) The NOESY correlations between $^2\text{CH}_2$ (4.35 and 4.82 ppm) and CH_3 (1.42 and 1.45 ppm), and between $^4\text{CH}_2$ (2.09–2.20 ppm) and the vinyl proton (5.51 and 5.53 ppm), confirmed the stereochemistry of (*Z*)-1 (see NOESY interactions in the Supporting Information).

all three molecules could derive from the same biogenetic pathway.

In order to confirm that the structure of barmumycin is actually that of *E*-16, we synthesized the latter and subsequently compared it to an authentic sample of the former. This began with selective silyl protection of the primary alcohol in the commercially available *N*-Boc-*trans*-4-hydroxy-*L*-prolinol followed by oxidation of the secondary alcohol in the derivative 17, which afforded ketone 18 in 62% yield over two steps (Scheme 4). Wittig chemistry was again employed to introduce the ethylidene chain: reaction of 18 with the Wittig ylide derived from ethyl-triphenylphosphonium bromide yielded 19 as a 9:1 mixture of *Z*/*E*-diastereomers. *Z*/*E*-19 was used directly without separation, as a single purification was planned for the final step of the synthesis. The TMS ether and the *tert*-butyl carbamate of *Z*/*E*-19 were deprotected with 10% TFA in CH_2Cl_2 to give the pyrrolidine derivative *Z*/*E*-20. Condensation of *Z*/*E*-20 to vanillic acid using (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and *N,N*-diisopropylethylamine (DIEA) gave a 9:1 mixture of *Z*/*E*-16 diastereomers. The configuration of the double bond was established by the NOESY correlations in *Z*/*E*-16 between $^5\text{CH}_2$ (4.00–4.20 ppm) and the CH_3 (1.60 ppm) (see NOESY correlations in the Supporting Information).

None of the Horner–Wadsworth–Emmons reactions tested (using the appropriate phosphonate and different bases¹⁹) gave

(19) The reaction was performed with $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CH}_3$ and either LDA, K^tBuO , or NaHMDS as base.

SCHEME 3. Route B for the Synthesis of 10




FIGURE 3. Structure proposed for barmumycin upon re-evaluation of NMR data.

the desired *E*-19. However, the Kocienski variant of the Julia–Lythgoe olefination²⁰ afforded a 2:1 mixture of *E/Z*-19. This process entails nucleophilic addition of 5-(ethylsulfonyl)-1-phenyl-1*H*-tetrazole anion to the ketone followed by transposition and elimination to give the double bond. Again, deprotection of the hydroxyl group and the amine group was obtained using 10% TFA in CH_2Cl_2 , and condensation of *E/Z*-20 to vanillic acid using PyBOP and DIEA gave a 2:1 mixture of *E/Z*-16. This mixture was purified by semipreparative HPLC to obtain *E*-16 as a single diastereomer. The configuration of the double bond was established by the NOESY correlations in *E*-16 between $^5\text{CH}_2$ (4.00–4.22 ppm) and the vinyl proton (5.30–5.38 ppm) (see the NOESY correlations in the Supporting Information).

Comparison of spectroscopic data obtained for *E*-16 and barmumycin confirmed that the revised structure is indeed the structure of the natural product.

In summary, the previously unreported marine compound barmumycin was isolated, and its chemical formula was determined via mass spectrometry. On the basis of preliminary NMR data, barmumycin was initially assigned the structure of compound 1. To confirm this assignment, compound 1 was synthesized following two different strategies starting from an *o*-aminobenzoate ester: one based on reductive amination, and one based on *N*-alkylation, which was shorter and higher yielding. However, comparison of the NMR spectra for 1 with those for isolated barmumycin showed dramatic differences. The structure of barmumycin was reassessed, and most probable option conceived was compound *E*-16,

which was subsequently prepared (in five steps and 18% overall yield) for comparison with the natural compound. The spectroscopic data for *E*-16 fully coincided with that for barmumycin, thereby confirming that the two structures are equivalent. This work is a new example of the importance of total synthesis for structural characterization and confirmation of natural products.²¹

Experimental Section


See the Supporting Information for general procedures.

Extraction and Isolation of Barmumycin. The culture broth (10 L) was separated by filtration into a mycelial cake and cultured filtrate (9 L). A 500 mL aliquot of the absorber resin XAD-1180 was added to the filtrate. Compound barmumycin was eluted from the resin by double extraction with a 3:1:1 mixture of EtOAc–MeOH– H_2O (1.8 L). The active fractions were concentrated in the organic phase, which was concentrated to dryness in vacuo to yield 950 mg of crude extract. This extract purified by vacuum flash chromatography using a mixture of *n*-hexane–EtOAc and EtOAc–MeOH, whereby the fractions containing barmumycin (220 mg) were eluted with 9:1 EtOAc–MeOH. The active fractions were purified by silica gel chromatography using CHCl_3 –MeOH mixtures. Cytotoxicity was detected in the fractions eluted with 96:4 CHCl_3 –MeOH (20 mg). Further purification with a C18 column by HPLC afforded 6 mg of pure barmumycin (elution with 54:46 H_2O /MeOH). This quantity of barmumycin was treated with 0.5 mL of pyridine and 0.5 mL of Ac_2O to afford 7 mg of the corresponding diacetate. The molecular formula of barmumycin was determined to be $\text{C}_{15}\text{H}_{19}\text{NO}_4$ by HPLC–APESI MS, in which it gave an $(\text{M} + \text{Na})^+$ peak at 300 and $(\text{M} - \text{H})^-$ 276. Barmumycin gave an $(\text{M} + \text{H})^+$ peak at 278 and $(\text{M} - \text{H})^-$ 276 in HPLC–APCI MS and it gave an $(\text{M} + \text{H})^+$ ion at m/z 278.13840 (calcd m/z 278.13869 for $\text{C}_{15}\text{H}_{20}\text{NO}_4$) in HRMALDI-TOF MS.

The diacetyl derivative of barmumycin gave an $(\text{M} + \text{H})^+$ peak at 362 and an $(\text{M} + \text{Na})^+$ peak at 384 by HPLC–APCI MS and HPLC–ESI MS.

(20) Blakemore, P. R. *J. Chem. Soc., Perkin Trans. 1* **2002**, 2563–2585.

(21) (a) Nicolaou, K. C.; Snyder, S. A. *Angew. Chem., Int. Ed.* **2005**, *44*, 1012–1044. (b) Cornella, I.; Kelly, T. R. *J. Org. Chem.* **2004**, *69*, 2191–2193.

SCHEME 4. Preparation of *Z/E*-16 Starting from *N*-Boc-*trans*-4-hydroxy-L-prolinol

2-Acetoxy-pent-4-enal (4). LiBF₄ (6.05 g, 64.5 mmol) was added to a solution of **3** (4.05 g, 21.5 mmol) in 98:2 MeCN/H₂O (110 mL), and the mixture was stirred for 72 h at room temperature. The solvents were removed in vacuo. The crude was dissolved in CH₂Cl₂, washed with water and brine, and then concentrated in vacuo to yield **4** (2.82 g, 92%) as a yellowish oil. IR (KBr film): ν 3080, 2932, 1744, 1373, 1237, 1048 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 2.18 (s, 3H); 2.32–2.65 (m, 2H); 5.06–5.30 (m, 3H); 5.65–5.87 (m, 1H); 9.54 (s, 1H). ¹³C NMR (100.6 MHz, CDCl₃): δ 20.4 (q); 33.1 (t); 77.2 (d); 119.0 (t); 131.4 (d); 170.4 (s); 197.9 (d). MS (ESI-TOF): 143 (M + 1, 100).

Methyl 2-(2-(2-Acetoxy-pent-4-enylamino)-5-methoxybenzoate (6a). PhSiH₃ (2.01 g, 18.6 mmol) was added to a THF solution (12 mL) of **5** (2.02 g, 9.3 mmol), **4** (1.32 g, 9.3 mmol), and Bu₂SnCl₂ (282.3 mg, 0.9 mmol) in a sealed tube. The mixture was heated to 100 °C under MW irradiation for 15 min. The solvents were removed in vacuo. Purification by silica gel column chromatography (100:0 to 95:5 hexane–Et₂O) yielded **6a** (1.93 g, 67%) as a yellowish oil. IR (KBr film): ν 3479, 3370, 2951, 1739, 1691, 1520, 1223, 1042 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 2.06 (s, 3H, Me); 2.41–2.46 (m, 2H); 3.35–3.37 (m, 2H); 3.76 (s, 3H, OMe); 3.86 (s, 3H, OMe); 5.09–5.17 (m, 3H); 5.78 (ddt, *J* = 17.2, 10.1, and 7.1 Hz, 1H); 6.74 (d, *J* = 9.2 Hz, 1H); 7.04 (dd, *J* = 9.2, 3.1 Hz, 1H); 7.42 (d, *J* = 3.1 Hz, 1H); 7.55 (bs, 1H, NH). ¹³C NMR (100.6 MHz, CDCl₃): δ 21.0 (q); 36.3 (t); 45.6 (t); 51.5 (q); 55.9 (q); 71.6 (d); 110.2 (s); 112.9 (d); 114.3 (d); 118.3 (t); 123.3 (d); 133.0 (d); 146.0 (s); 149.5 (s); 168.6 (s); 170.6 (s). MS (ESI-TOF): 308 (M + 1, 82). HRMS: *m/z* calcd. for C₁₆H₂₂NO₅ 308.1498, found 308.1504.

Methyl 2-(2-(2-Hydroxy-pent-4-enylamino)-5-methoxybenzoate (6b). K₂CO₃ (953.5 mg, 6.9 mmol) was added to a solution of **6a** (1.92 g, 6.27 mmol) in MeOH (75 mL). The mixture was stirred for 1 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in CH₂Cl₂ and then washed with water and brine. The organic extracts were dried over MgSO₄ and then concentrated in vacuo. Purification by silica gel column chromatography (85:15 to 75:25 hexane/EtOAc) yielded **6b** (1.55 g, 93%) as a yellow oil. IR (KBr film): ν 3370, 1688, 1518, 1437, 1222, 1073 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 2.27–2.43 (m, 2H); 3.20 (dd, *J* = 13.0 and 7.7 Hz, 1H); 3.33 (dd, *J* = 13.0 and 4.5 Hz, 1H); 3.77 (s, 3H, OMe); 3.87 (s, 3H, OMe); 3.96 (m, 1H); 5.17 (m, 1H); 5.19 (m, 1H); 5.87 (m, 1H); 6.75 (d, *J* = 9.1 Hz, 1H); 7.04 (dd, *J* = 9.1, 3.1 Hz, 1H); 7.44 (d,

J = 3.1 Hz, 1H). ¹³C NMR (100.6 MHz, CDCl₃): δ 39.5 (t); 49.3 (t); 51.7 (q); 56.0 (q); 69.3 (d); 110.8 (s); 113.6 (d); 114.5 (d); 118.5 (t); 123.2 (d); 133.9 (d); 145.8 (s); 149.9 (s); 168.6 (s). MS (ESI-TOF): 266 (M + 1, 100). HRMS: *m/z* calcd for C₁₄H₂₀NO₄ 266.1392, found 266.1398.

Methyl 2-(2-(*tert*-Butoxycarbonyloxy)pent-4-enylamino)-5-methoxybenzoate (6c). Boc₂O (823 mg, 3.77 mmol) was added to a solution of **6b** (909.4 mg, 3.43 mmol) and DMAP (125.6 mg, 1.03 mmol) in dry CH₂Cl₂ (50 mL). The reaction mixture was stirred for 40 h at room temperature and then concentrated in vacuo. Purification by silica gel column chromatography (100:0 to 95:5 hexane–EtOAc) yielded **6c** (543 mg, 43%) as a yellowish oil. IR (KBr film): ν 3369, 3078, 1730, 1709, 1500, 1368 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.47 (s, 9H); 2.41–2.48 (m, 2H); 3.39 (d, *J* = 6.1 Hz, 2H); 3.76 (s, 3H, OMe); 3.85 (s, 3H, OMe); 4.91 (p, *J* = 6.1 Hz, 1H); 5.12 (m, 1H); 5.17 (m, 1H); 5.82 (m, 1H); 6.74 (d, *J* = 9.2 Hz, 1H); 7.04 (dd, *J* = 9.2, 3.1 Hz, 1H); 7.42 (d, *J* = 3.1 Hz, 1H). ¹³C NMR (100.6 MHz, CDCl₃): δ 27.7 (q); 36.5 (t); 45.9 (t); 51.6 (q); 56.0 (q); 74.4 (d); 82.2 (s); 110.4 (s); 112.9 (d); 114.4 (d); 118.4 (t); 123.3 (d); 132.9 (d); 145.8 (s); 149.6 (s); 153.2 (s); 168.5 (s). MS (ESI-TOF): 366 (M + 1, 100). HRMS: *m/z* calcd for C₁₉H₂₈NO₆ 366.1917, found 366.1917.

Methyl 2-[*N*-(2-(*tert*-Butoxycarbonyloxy)pent-4-enyl)trifluoroacetamido]-5-methoxybenzoate (6d). TFAA (0.3 mL, 2.2 mmol) was added to a cooled (0 °C) solution of **6c** (542.9 mg, 1.49 mmol) in pyridine (20 mL), and the mixture was stirred at 0 °C for 90 min. The crude was concentrated in vacuo, dissolved in CH₂Cl₂, and then washed with NH₄Cl, water, and brine. The organic extracts were dried over MgSO₄ and then concentrated in vacuo to yield **6d** as a mixture of rotamers (685 mg, quant) as a yellowish oil. IR (KBr film): ν 1736, 1707, 1502, 1282 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.42 and 1.47 (2s, 9H); 2.32–2.40 (m, 2H, CH₂); 3.04 and 3.31 (2dd, *J* = 14.4, 9.3 and 14.8, 2.2 Hz, 1H, CH₂); 3.86 (s, 3H, OMe); 3.87 (s, 3H, OMe); 4.41 and 4.51 (2dd, *J* = 14.4, 2.9 and 14.8, 8.9 Hz, 1H, CH₂); 4.82–4.87 and 5.17–5.23 (2m, 1H, CH); 5.05–5.17 (m, 2H); 5.65–5.81 (m, 1H); 7.04 and 7.10 (2dd, *J* = 8.8, 3.0 Hz, 1H); 7.24 and 7.51 (2d, *J* = 8.8 Hz, 1H); 7.55 and 7.57 (2d, *J* = 3.0 Hz, 1H). ¹³C NMR (100.6 MHz, CDCl₃): δ 27.6 and 27.7 (3q); 36.7 and 37.1 (t); 52.7 (q); 54.0 and 55.8 (t); 55.7 (q); 73.3 and 73.7 (d); 82.3 (s); 116.4 and 116.8 (d); 118.5 and 118.7 (d); 118.6 (t); 132.2 and 132.3 (d); 132.7 (d); 152.7 (s); 153.1 (s); 159.6 and 159.7 (s); 164.8 and 164.9 (s); 171.1 (s). ¹⁹F NMR (376 MHz, CDCl₃): δ -68.8 and -69.0 (2s). MS (ESI-TOF): 945 (2M + Na, 15). HRMS: *m/z* calcd for C₄₂H₅₂N₂O₁₄F₆Na 945.3220, found 945.3208.

Methyl 5-Methoxy-2-[N-(2-hydroxypent-4-enyl)trifluoroacetamido]benzoate (6e). A 10% solution of TFA in CH_2Cl_2 (50 mL) was added to **6d** (494.9 mg, 1.07 mmol), and the mixture was stirred at room temperature for 25 min. Elimination of the solvent gave **6e** (387 mg, quant) as a yellow oil. IR (KBr film): ν 3370, 2950, 1688, 1519, 1437, 1222, 1074 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 2.20–2.30 (m, 2H, CH_2); 3.46–3.49 and 3.54–3.61 (m, 1H); 3.88 (s, 3H, OMe); 3.90 (s, 3H, OMe); 4.02–4.15 (m, 2H); 4.89 (bs, 1H, OH); 5.10–5.14 (m, 2H); 5.72–5.81 (m, 1H); 7.09–7.14 (m, 1H); 7.31 and 7.39 (2d, $J = 8.8$ Hz, 1H); 7.55 (d, $J = 2.5$ Hz, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 39.3 and 39.4 (t); 52.9 (q); 55.8 (q); 58.4 and 59.0 (t); 68.2 and 68.8 (d); 114.9 (s); 116.2 and 116.7 (d); 118.8 (t); 118.9 and 119.0 (d); 120.1 (s); 120.9 (s); 122.8 (s); 131.1 (s); 131.9 and 132.1 (d); 133.1 and 133.4 (d); 159.8 (s). ^{19}F NMR (376 MHz, CDCl_3): δ –68.7 (s). MS (ESI-TOF): 362 ($M + 1$, 37). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{19}\text{NO}_5\text{F}_3$ 362.1215, found 362.1211.

Methyl 5-Methoxy-2-[N-(2-oxopent-4-enyl)trifluoroacetamido]benzoate (7). Dess–Martin periodinane (606.4 mg, 1.43 mmol) was added to a solution of **6e** (469.6 mg, 1.30 mmol) in anhydrous CH_2Cl_2 (35 mL). The mixture was stirred for 1 h and then diluted with Et_2O and hexane to a final concentration of 30:20:50 $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$ /hexane. The solution was filtered through a silica gel pad. The solvents were removed in vacuo to yield **7** (433 mg, 93%) as a yellowish oil. IR (KBr film): ν 1707, 1704, 1502, 1291, 1204, 1153 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 3.18 (dd, $J = 16.8$ and 6.7 Hz, 1H); 3.27 (dd, $J = 16.8$ and 7.2 Hz, 1H); 3.85 (m, 1H); 3.86 (s, 3H, OMe); 3.89 (s, 3H, OMe); 5.13–5.23 (m, 3H); 5.95 (m, 1H); 7.06 (dd, $J = 8.8$ and 3.0 Hz, 1H); 7.51 (d, $J = 3.0$ Hz, 1H); 7.59 (d, $J = 8.8$ Hz, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 45.0 (t); 52.7 (q); 55.7 (q); 60.4 (t); 114.7 (s); 116.5 (d); 117.6 (s); 118.4 (d); 119.9 (t); 129.0 (s); 129.1 (d); 131.6 (s); 132.6 (d); 159.8 (s); 165.0 (s); 200.8 (s). ^{19}F NMR (376 MHz, CDCl_3): δ –68.8 (s). MS (ESI-TOF): 360 ($M + 1$, 100). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_5\text{F}_3$ 360.1059, found 360.1072.

Methyl 5-Methoxy-2-[N-(2,4,5-trihydroxypent-2-enyl)trifluoroacetamido]benzoate (8). A solution of **7** (775 mg, 2.16 mmol) in acetone (20 mL) was added dropwise over 10 h to a stirring solution of *N*-methylmorpholine oxide (337 mg, 2.37 mmol) and OsO_4 (catalytic amount) in 60:40 acetone/ H_2O (64 mL). The mixture was stirred for 20 h at room temperature, quenched with 40% aq NaHSO_3 (3 mL), and subsequently concentrated in vacuo. The residue was dissolved in EtOAc, dried over MgSO_4 , filtered, and then reconcentrated in vacuo. Purification by silica gel column chromatography (100:0 to 90:10 CH_2Cl_2 –MeOH) yielded **8** (628 mg, 84%) as a brownish oil. IR (KBr film): ν 1725, 1605, 1503, 1293, 1204 cm^{-1} . ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 3.25–3.30 (m, 1H); 3.36–3.43 (m, 1H); 3.63–3.71 (m, 1H, CH); 3.84 (s, 6H, 2OMe); 4.12–4.13 (m, 1H); 4.16 and 4.33 (2d, $J = 18.5$ Hz, 1H); 5.14 and 5.33 (2d, $J = 18.5$ Hz, 1H); 7.27 and 7.29 (2dd, $J = 3.0$ Hz, 1H); 7.41–7.48 (m, 2H). ^{13}C NMR (100.6 MHz, $\text{DMSO}-d_6$): δ 52.6 (q); 55.7 (q); 59.4 and 60.2 (t); 61.3 (t); 72.2 and 72.9 (d); 76.0 and 76.1 (d); 116.0 (d); 118.5 (d); 128.6 (s); 128.7 (s); 131.2 (s); 131.9 (d); 159.2 (s); 164.4 (s); 206.2 (s); 207.5 (s). ^{19}F NMR (376 MHz, CDCl_3): δ –68.8 (s). MS (ESI-TOF): 392 ($M - 1$, 100); 394 ($M + 1$, 40). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{17}\text{NO}_7\text{F}_3$ 392.0957, found 392.0946.

Methyl 2-[N-(3-(2,2-Dimethyl-1,3-dioxolan-4-yl)-2-oxopropyl)trifluoroacetamido]-5-methoxybenzoate (9). Pyridinium *p*-toluenesulfonate (18.7 mg, 74 mmol) was added to a solution of **8** (584 mg, 1.49 mol) and 2,2-dimethoxypropane (1.82 mL, 14.8 mmol) in CH_2Cl_2 (30 mL). The mixture was stirred at 40 °C for 16 h and then concentrated in vacuo. Purification by silica gel column chromatography (90:10 to 40:60 hexane–EtOAc) yielded **9** (642 mg, quant) as a yellowish oil. IR (KBr film): ν 1775, 1730, 1381, 1172, 1087, 1047 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 1.30 and 1.36 (2s, 6H); 2.59 and 2.69 (2dd, $J = 16.3$, 6.8 and 16.7, 6.0 Hz, 1H, CH_2); 2.81 and 2.90 (2dd, $J = 16.7$, 6.8 and 16.3, 6.0 Hz, 1H, CH_2); 3.54 and 3.60 (2dd, $J = 8.4$, 6.6 Hz, 1H); 3.77–3.83 (m, 1H);

3.85 (s, 3H, OMe); 3.87 (s, 3H, OMe); 4.12–4.18 (m, 1H); 4.40–4.48 (m, 1H); 5.08 (d, $J = 17.9$ Hz, 1H); 5.13 (d, $J = 17.9$ Hz, 1H); 7.048 and 7.051 (2dd, $J = 8.8$ and 3.0 Hz, 1H); 7.50 (d, $J = 3.0$ Hz, 1H); 7.55 and 7.57 (2d, $J = 8.8$ Hz, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 25.4 (q); 26.8 (q); 44.3 and 44.4 (t); 52.6 (q); 55.7 (q); 61.2 and 61.4 (t); 69.0 and 69.2 (t); 71.3 (d); 109.1 (s); 114.6 (s); 116.4 and 116.5 (d); 117.5 (s); 118.4 (d); 129.0 (s); 131.6 (s); 132.5 and 132.6 (d); 159.8 (s); 164.9 (s); 200.8 (s). ^{19}F NMR (376 MHz, CDCl_3): δ –68.8 (s). MS (ESI-TOF): 434 ($M + 1$, 100).

Isobutyl 3,4-Dihydroxybutanoate (11). A solution of isobutyl but-3-enoate (10.5 g, 73.6 mmol) in acetone (50 mL) was added dropwise over 20 h to a solution of *N*-methylmorpholine oxide (10.9 g, 80.9 mmol) and a catalytic amount OsO_4 in 60:40 acetone/ H_2O (250 mL). The reaction was quenched with NaHSO_3 40% aq solution (3 mL) and concentrated in vacuo. The crude was dissolved in EtOAc and filtered through silica gel, and the eluent was concentrated in vacuo to yield **11** (12.6 g, 97%) as a yellow oil. IR (KBr film): ν 3402, 2962, 1729, 1470, 1381, 1170, 1043 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 0.94 (d, $J = 6.8$ Hz, 6H); 2.00–1.89 (m, 1H); 2.51 (dd, $J = 16.4$ and 4.0 Hz, 1H, CH_2); 2.58 (dd, $J = 16.4$ and 8.4 Hz, 1H, CH_2); 3.58 (dd, $J = 11.2$ and 6.4 Hz, 1H, CH_2); 3.69 (dd, $J = 11.2$ and 3.6 Hz, 1H, CH_2); 3.91 (d, $J = 6.8$ Hz, 2H); 4.10–4.18 (m, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 19.2 (2q); 27.8 (d); 37.9 (t); 65.9 (t); 68.8 (d); 71.2 (t); 172.8 (s). MS (ESI-TOF): 177 ($M + 1$, 45); 199 ($M + \text{Na}$, 100). HRMS (+ESI): m/z calcd for $\text{C}_8\text{H}_{17}\text{O}_4$ ($M + 1$) 177.1127, found 177.1127; calcd for $\text{C}_8\text{H}_{16}\text{O}_4\text{Na}$ ($M + \text{Na}$) 199.0946, found 199.0945.

Isobutyl 2,2-Dimethyl-1,3-dioxolan-4-yl acetate (12). Pyridinium *p*-toluenesulfonate (120 mg, 0.48 mmol) was added to a solution of **11** (15.4 g, 87.26 mmol) in 50:50 2,2-dimethoxypropane/ CH_2Cl_2 (300 mL). The reaction mixture was stirred at room temperature for 16 h, and then the solvent was removed in vacuo. Purification by silica gel column chromatography (50:50 hexane–EtOAc) yielded **12** (17.4 g, 92%) as a yellowish oil. IR (KBr film): ν 1736, 1380, 1370 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 0.93 (d, $J = 6.8$ Hz, 6H); 1.35 (s, 3H); 1.41 (s, 3H); 1.98–1.87 (m, 1H); 2.52 (dd, $J = 15.7$ and 7.6 Hz, 1H, CH_2); 2.72 (dd, $J = 15.7$ and 6.4 Hz, 1H, CH_2); 3.65 (dd, $J = 8.4$ and 6.4 Hz, 1H, CH_2); 3.88 (d, $J = 6.4$ Hz, 2H); 4.16 (dd, $J = 8.4$ and 6.0 Hz, 1H, CH_2); 4.40–4.51 (m, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 19.0 (2q); 25.5 (q); 26.9 (q); 27.6 (d); 39.0 (t); 69.2 (t); 70.8 (t); 72.1 (d); 109.1 (s); 170.6 (s).

1-Bromo-3-(2,2-dimethyl-1,3-dioxolan-4-yl)propan-2-one (13). A 1.6 M solution of MeLi in Et_2O (5 mL, 8 mmol) was added to a solution of **12** (865 mg, 4 mmol) and dibromomethane (557 μL , 8 mmol) in THF (20 mL) at –116 °C. The solution was stirred for 3 h and then quenched with satd NH_4Cl (60 mL). The residue was immediately extracted with CH_2Cl_2 . The organic layers were dried over MgSO_4 , filtered, and then concentrated in vacuo. Purification by silica gel column chromatography (80:20 to 70:30 hexane–EtOAc) yielded **13** (460 mg, 49%) as a yellow oil. IR (KBr film): ν 1719, 1370, 840 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 1.35 (s, 3H); 1.42 (s, 3H); 2.82 (dd, $J = 16.6$ and 6.0 Hz, 1H, CH_2); 3.07 (dd, $J = 16.6$ and 6.8 Hz, 1H, CH_2); 3.60 (dd, $J = 8.4$ and 6.4 Hz, 1H, CH_2); 3.94 (s, 2H); 4.18 (dd, $J = 8.4$ and 6.0 Hz, 1H, CH_2); 4.44–4.51 (m, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 25.4 (q); 26.8 (q); 34.6 (t); 44.16 (t); 69.2 (t); 71.8 (d); 109.3 (s); 199.7 (s). MS (ESI-TOF): 259 ($\text{MBr}^{79} + \text{Na}$, 100); 261 ($\text{MBr}^{81} + \text{Na}$, 98). HRMS (+ESI): m/z calcd for $\text{C}_8\text{H}_{13}\text{O}_3\text{NaBr}$ ($M + \text{Na}$) 258.9944, found 258.9946.

Methyl 2-[3-(2,2-Dimethyl-1,3-dioxolan-4-yl)-2-oxopropylamino]-5-methoxybenzoate (10). **Route A.** K_2CO_3 (68 mg, 0.5 mmol) was added to a solution of **9** (50 mg, 0.11 mmol) in MeOH, and the mixture was stirred for 1 h. The solvent was removed in vacuo, and the resulting residue was purified by silica gel column chromatography (95:5 to 80:20 hexane/EtOAc) to yield **10** (38 mg, 97%) as a yellowish oil.

Route B. 2,6-Lutidine (1.6 mL, 13.74 mmol) and tetrabutylammonium iodide (3.08 g, 8.33 mmol) were added to a solution of **5** (1.21 g, 6.66 mmol) and **13** (1.37 g, 5.76 mmol) in 1,4-dioxane

(12 mL). The reaction mixture was stirred at 40 °C for 15 min under microwave irradiation. Purification by silica gel column chromatography (95:5 to 80:20 hexane–EtOAc) yielded **10** (1.44 g, 74%) as a yellow oil. IR (KBr film): ν 3350, 1705, 1692, 1521, 1286, 1225, 1045 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 1.34 (s, 3H); 1.40 (s, 3H); 2.64 (dd, $J = 16.2, 6.5$ Hz, 1H, CH_2); 2.94 (dd, $J = 16.2, 6.5$ Hz, 1H, CH_2); 3.58 (dd, $J = 8.4, 6.7$ Hz, 1H); 3.76 (s, 3H, OMe); 3.89 (s, 3H, OMe); 4.08 (bd, 2H, CH_2); 4.18 (dd, $J = 8.4$ and 6.0 Hz, 1H); 4.46–4.52 (m, 1H); 6.46 (d, $J = 9.1$ Hz, 1H); 7.02 (dd, $J = 9.1$ and 3.1 Hz, 1H); 7.45 (d, $J = 3.1$ Hz, 1H); 7.99 (bt, 1H, NH). ^{13}C NMR (100.6 MHz, CDCl_3): δ 25.4 (q); 26.8 (q); 44.2 (t); 51.7 (q); 54.2 (t); 55.9 (q); 69.3 (t); 71.8 (d); 109.1 (s); 110.8 (s); 112.7 (d); 114.8 (d); 123.1 (d); 144.7 (s); 149.9 (s); 168.4 (s); 204.7 (s). MS (ESI-TOF): 338 ($M + 1$, 47); 675 ($2M + 1$, 100). HRMS: m/z calcd for $\text{C}_{17}\text{H}_{24}\text{NO}_6$ 338.1598, found 338.1603.

(*Z/E*)-Methyl 2-[2-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]but-2-enylamino]-5-methoxybenzoate (*Z/E*-**14**). A 2.5 M solution of BuLi in hexane (1.27 mL, 3.17 mmol) was added to a mixture of ethyltriphenylphosphonium bromide (1.18 g, 3.17 mmol) in anhydrous THF (13 mL). The reaction mixture was stirred at room temperature for 1 h and then cooled to -78 °C. A solution of **10** (337 mg, 1.58 mmol) in anhydrous THF (3 mL) was added dropwise to the reaction mixture. The reaction mixture was stirred at -78 °C for 30 min and subsequently allowed to warm to room temperature for an additional 30 min. The solvent was removed in vacuo, and the residue was purified by silica gel column chromatography with hexane–EtOAc (95:5 to 80:20) to yield *Z*-**14** and *E*-**14** as a yellowish oil (239 mg, 43%; 73:27 *Z/E*, as determined by ^1H NMR). IR (KBr film): ν 3373, 1689, 1517, 1222, 1065 cm^{-1} . *Z*-**14**. ^1H NMR (400 MHz, CDCl_3): δ 1.33 (s, 3H); 1.40 (s, 3H); 1.74 (d, $J = 6.9$ Hz, 3H); 2.23–2.44 (m, 2H, CH_2); 3.53 (dd, $J = 7.8$ and 7.4 Hz, 1H); 3.76 (s, 3H, OMe); 3.82 (bs, 2H, CH_2); 3.85 (s, 3H, OMe); 4.00 (dd, $J = 7.8$ and 6.0 Hz, 1H); 4.19–4.26 (m, 1H); 5.56 (q, $J = 6.9$ Hz, 1H); 6.63 (d, $J = 9.2$ Hz, 1H); 7.03 (dd, $J = 9.2$ and 3.2 Hz, 1H); 7.42 (d, $J = 3.2$ Hz, 1H). *E*-**14**. ^1H NMR (100.6 MHz, CDCl_3): δ 1.35 (s, 3H); 1.43 (s, 3H); 1.65 (d, $J = 6.9$ Hz, 3H); 2.23–2.44 (m, 2H, CH_2); 3.56 (dd, $J = 7.6$ and 7.6 Hz, 1H); 3.75 (s, 3H, OMe); 3.82 (bs, 2H, CH_2); 3.86 (s, 3H, OMe); 4.02–4.05 (m, 1H); 4.19–4.26 (m, 1H); 5.62 (q, $J = 6.9$ Hz, 1H); 6.63 (d, $J = 9.2$ Hz, 1H); 7.00 (dd, $J = 9.2$ and 3.1 Hz, 1H); 7.41 (d, $J = 3.1$ Hz, 1H). ^{13}C NMR (400 MHz, CDCl_3): δ 13.4 (q); 25.7 (q); 27.0 (q); 32.6 and 42.8 (t); 40.0 (t); 51.5 (q); 56.0 (q); 69.3 (t); 75.0 (d); 108.9 (s); 112.8 and 114.1 (d); 114.4 (d); 123.3 (d); 125.4 (d); 133.0 (s); 133.7 (s); 146.4 (s); 149.4 (s); 168.6 (s). MS (ESI-TOF): 350 ($M + 1$, 35); 372 ($M + \text{Na}$, 45); 721 ($2M + \text{Na}$, 100). HRMS: m/z calcd for $\text{C}_{19}\text{H}_{28}\text{NO}_5$ 350.1962, found 350.1961.

(*Z*)-2-[2-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]but-2-enylamino]-5-methoxybenzoic Acid (*Z*-**15**). LiOH (310 mg, 7.39 mmol) was added to a solution of *Z/E*-**14** (258 mg, 0.74 mmol) in 75:25 $\text{H}_2\text{O}/\text{THF}$ (20 mL). The reaction mixture was sonicated at room temperature for 1 h and then stirred at 50 °C for 24 h. The crude mixture was washed with Et_2O . The aqueous phase was cooled to 0 °C, acidified to pH 7 with 4 M HCl (1.7 mL), and extracted with CH_2Cl_2 . The combined organic extracts were dried over MgSO_4 and then concentrated in vacuo to yield *Z/E*-**15** (250 mg, quant; 73:27 *Z/E*, as determined by ^1H NMR) as a yellowish oil. Purification by semipreparative HPLC performed on a 15.5 g Redispex Gold C_{18} (20–40 μm) column, with UV detection at 254 nm, a flow rate of 18 mL/min, and $\text{H}_2\text{O}-\text{CH}_3\text{CN}$ as eluents (gradient: 80:20 to 60:40 in 50 min), yielded *Z*-**15** (80 mg, 72% recovery). IR (KBr film): ν 3375, 2985, 1668, 1577, 1516, 1371, 1216, 1041 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 1.34 (s, 3H); 1.42 (s, 3H); 1.74 (d, $J = 6.9$ Hz, 3H); 2.27 (dd, $J = 14.3$ and 5.7 Hz, 1H, CH_2); 2.41 (dd, $J = 14.3$ and 7.1 Hz, 1H, CH_2); 3.55 (t, $J = 8.0$ Hz, 1H); 3.78 (s, 3H, OMe); 3.86 (bs, 2H); 4.02 (dd, $J = 8.0$ and 6.0 Hz, 1H); 4.20–4.27 (m, 1H); 5.58 (q, $J = 6.9$ Hz, 1H); 6.69 (d, $J = 9.1$ Hz, 1H); 7.08 (dd, $J = 9.1$ and 3.1 Hz, 1H); 7.49 (d, $J = 3.1$ Hz, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ 13.5 (q); 25.7 (q); 27.0 (q); 39.8 (t); 43.3 (t); 56.0

(q); 69.2 (t); 75.1 (d); 109.1 (s); 109.8 (s); 113.9 (d); 114.6 (d); 124.5 (d); 125.8 (d); 133.3 (s); 146.3 (s); 150.0 (s); 172.5 (s). MS (ESI-TOF): 336 ($M + 1$, 100); 337 ($M + 2$, 23).

(*Z*)-3-Ethylidene-5-hydroxy-10-methoxy-1,2,3,4,5,6-hexahydrobenzo[*c*][1,5]oxazecin-8-one (**1**). *Z*-**15** (30 mg, 0.09 mmol) was stirred with 4 M HCl (4 mL) for 30 min and then concentrated in vacuo to yield (*Z*)-2-(2-ethylidene-4,5-dihydroxypentylamino)-5-methoxybenzoic acid hydrochloride. The resulting residue was used in the following step without further purification. A mixture of EDC·HCl (69 mg, 0.36 mmol), (*Z*)-2-[2-ethylidene-4,5-dihydroxypentylamino]-5-methoxybenzoic acid hydrochloride, solid-supported DMAP (18 mg, 0.09 mmol), and molecular sieves 4 Å (254 mg) in dry CH_2Cl_2 (20 mL) was stirred at room temperature for 3 h. The crude mixture was filtered, treated with satd NH_4Cl , and then extracted with CH_2Cl_2 . The combined organic extracts were dried over MgSO_4 and then concentrated in vacuo. Purification by silica gel column chromatography (100:0 to 80:20 $\text{CH}_2\text{Cl}_2/\text{MeOH}$) yielded **Z-1** as a brownish oil (9 mg, 35%). IR (KBr film): ν 3397, 1640, 1498, 1436, 1292, 1228, 1039 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 1.42 and 1.45 (2d, $J = 6.9$ Hz, 3H); 2.09–2.20 (m, 2H, CH_2); 3.44–3.51 and 3.59–3.69 (2 m, 2H, CH_2); 3.73 (s, 3H, OMe); 3.79–3.90 (m, 1H); 4.35 (dd, $J = 14.3$ and 6.1 Hz, 1H, CH_2); 4.82 (dd, $J = 14.3, 3.1$ Hz, 1H, CH_2); 5.51 and 5.53 (2q, $J = 6.9$ Hz, 1H); 6.72–6.76 (m, 2H); 6.92 (2d, $J = 8.5, 1\text{H}$). ^{13}C NMR (100.6 MHz, CDCl_3): δ 13.4 (q); 38.2 and 38.9 (t); 46.9 and 47.1 (t); 55.5 (q); 66.2 and 66.8 (t); 70.4 and 70.9 (d); 111.5 and 111.6 (d); 116.5 (d); 127.0 and 127.1 (d); 127.9 and 128.4 (d); 130.2 and 130.5 (s); 130.7 (s); 136.1 and 136.2 (s); 158.9 (s); 169.1 and 169.2 (s). MS (ESI-TOF): 299 ($M + \text{Na}$, 13); 555 ($2M + 1$, 100); 577 ($2M + \text{Na}$, 100). HRMS: m/z calcd. for $\text{C}_{30}\text{H}_{38}\text{N}_2\text{O}_8\text{Na}$ 577.2520, found 577.2521.

(*2S,4R*)-1-*tert*-Butoxycarbonyl-4-hydroxy-2-(trimethylsilyloxy-methyl)pyrrolidine (**17**). TMSCl (0.65 mL, 4.85 mmol) was added to a solution of *N*-Boc-trans-4-hydroxy-L-prolinol (1.054 g, 4.85 mmol), Et_3N (0.67 mL, 4.85 mmol) in CH_2Cl_2 (25 mL). The reaction mixture was stirred at 0 °C for 16 h. After this time the reaction mixture was washed with water, dried over MgSO_4 , filtered, and the solvent was removed under reduced pressure. Purification by silica gel column chromatography with hexane–EtOAc (70:30 to 50:50) yielded **17** (1.05 g, 75%) as a colorless oil. IR (KBr film) ν 3434, 1692, 1678, 1408, 1119 cm^{-1} . ^1H NMR (400 MHz, CD_3OD) δ 0.12 and 0.13 (2s, 9H); 1.50 and 1.51 (2s, 9H); 1.90–2.04 (m, 1H, CH_2); 2.18 (dt, $J = 17.2$ and 5.8 Hz, 1H, CH_2); 3.35–3.48 (m, 2H, CH_2); 3.63 and 3.65 (2d, $J = 10.2$ Hz, 1H, CH_2); 3.78 and 3.90 (2dd, $J = 10.2$ and 4.6 Hz, 1H, CH_2); 3.94–4.02 (m, 1H, CH); 4.38–4.44 (m, 1H, CH). ^{13}C NMR (100.6 MHz, CD_3OD) δ -0.5 (q); 28.8 (q); 37.3 and 38.2 (t); 55.9 and 56.4 (t); 58.8 and 58.9 (d); 63.6 and 64.6 (t); 70.1 and 70.6 (d) 80.8 and 81.1 (s); 155.3 (s). HRMS m/z calcd. for $\text{C}_{13}\text{H}_{28}\text{NO}_4\text{Si}$ 290.1782, found 290.1784.

(*S*)-1-*tert*-Butoxycarbonyl-2-(trimethylsilyloxymethyl)pyrrolidin-4-one (**18**). DMP (369 mg, 0.87 mmol) was added to a solution of **17** (228 mg, 0.78 mmol) in CH_2Cl_2 (10 mL), and the reaction mixture was stirred at room temperature for 15 min. After this time, satd NaHCO_3 and satd $\text{Na}_2\text{S}_2\text{O}_3$ were added, and the reaction mixture was stirred for additional 10 min. The residue was extracted with CH_2Cl_2 , the combined organic extracts were dried over MgSO_4 and filtered, and the solvent was removed under reduced pressure. Purification by silica gel column chromatography with hexane–EtOAc (80:20) yielded **18** (182 mg, 82%) as a colorless oil. IR (KBr film): ν 1765, 1701, 1401, 1106 cm^{-1} . ^1H NMR (400 MHz, CD_3OD): δ 0.12 (s, 9H); 1.54 (s, 9H); 2.41 (d, $J = 18.0$ Hz, 1H, CH_2); 2.77–2.93 (m, 1H, CH_2); 3.57–3.68 (m, 2H, CH_2); 3.86 (d, $J = 18.0$ Hz, 1H, CH_2); 3.99 (dd, $J = 22.1, 10.0$ Hz, 1H, CH_2); 4.38 and 4.40 (2bs, 1H, CH). ^{13}C NMR (100.6 MHz, CD_3OD): δ -0.9 (q); 28.7 (q); 41.1 and 41.7 (t); 54.4 and 54.9 (t); 56.8 and 57.4 (d); 65.3 and 66.1 (t); 81.6 (s). HRMS: m/z calcd for $\text{C}_{13}\text{H}_{26}\text{NO}_4\text{Si}$ 288.1626, found 288.1628.

(*S,Z*)-1-*tert*-Butoxycarbonyl-4-ethylidene-2-((trimethylsilyloxy)-methyl)pyrrolidine (*Z*-19). ^tBuOK (213 mg, 1.9 mmol) was added to a solution of ethyltriphenylphosphonium bromide (705 mg, 1.9 mmol) in THF (5 mL), and the mixture was stirred for 1 h. After this time, **18** (180 mg, 0.62 mmol) was added, and the mixture was stirred for additional 30 min. Water was added, the residue was extracted with Et₂O, dried over MgSO₄, and filtered, and the solvent was removed under reduced pressure. Purification by silica gel column chromatography with hexane–EtOAc (95:5) yielded *Z/E*-19 (136 mg, 73%) in a 9:1 ratio as a colorless oil. IR (KBr film): ν 1702, 1397, 1251, 1109 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 0.09 (s, 9H); 1.48 (s, 9H); 1.58 (d, *J* = 6.8 Hz, CH₃); 2.45–2.54 (m, 1H, CH₂); 2.56–2.67 (m, 1H, CH₂); 3.20–3.45 (m, 1H, CH₂); 3.55–3.67 (m, 1H, CH₂); 3.78–4.05 (m, 3H, CH + CH₂); 5.32–5.40 (m, 1H, CH). ¹³C NMR (100.6 MHz, CDCl₃): δ -0.5 (q); 14.5 (q); 28.5 (q); 34.0 and 34.5 (t); 47.5 (t) 57.5 and 57.7 (d); 62.7 and 63.1 (t); 79.4 (s); 115.9 and 116.2 (d); 136.7 (s); 154.2 (s). HRMS: *m/z* calcd for C₁₅H₃₀NO₃Si 300.1989, found 300.1990.

(*S,Z*)-4-Ethylidene-2-(hydroxymethyl)pyrrolidine (*Z*-20). A solution of *Z/E*-19 in a 9:1 ratio (136 mg, 0.45 mmol) in 10% TFA in CH₂Cl₂ (5 mL) was stirred at room temperature for 1 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography with CH₂Cl₂–MeOH (98:2 to 90:10) to obtain *Z/E*-20 (105 mg) in a 9:1 ratio in quantitative yield. IR (KBr film): ν 3380, 1677, 1435, 1135 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.60 (d, *J* = 8.0 Hz, 3H, CH₃); 2.34–2.45 (m, 1H, CH₂); 2.58–2.68 (m, 1H, CH₂); 3.65–3.95 (m, 5H); 5.50–5.58 (m, 1H, =CH). ¹³C NMR (100.6 MHz, CDCl₃): δ 14.7 (q); 32.2 (t); 45.8 (t); 60.5 (t); 61.4 (d); 120.6 (d); 130.9 (s). HRMS: *m/z* calcd for C₇H₁₄NO 128.1069, found 128.1070.

(*S,Z*)-*N*-(4-Hydroxy-3-methoxybenzoyl)-4-ethylidene-2-(hydroxymethyl)pyrrolidine (*Z*-16). PyBOP (135 mg, 0.26 mmol) was added to a solution of DIEA (0.1 mL, 0.55 mmol) and vanillic acid (44 mg, 0.26 mmol) in THF (5 mL), and the mixture was stirred for 10 min. Then, a solution of *Z/E*-20 in a 9:1 ratio (26 mg, 0.21 mmol) in THF was added, and the mixture was stirred for 1 h. The solvent was removed under reduced pressure, and the residue was dissolved in EtOAc and washed with satd NaHCO₃ and satd NH₄Cl. Purification by silica gel column chromatography with EtOAc yielded *Z*-16 (45 mg, 73%) in a 9:1 ratio as a colorless oil. $[\alpha]_D^{25} = -21.5$ (*c* 0.75, CH₂Cl₂). IR (KBr film): ν 3288, 1600, 1585, 1431, 1277, 1207 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.60 (bs, 3H, CH₃); 2.27–2.40 (m, 1H, CH₂); 2.66–2.78 (m, 1H, CH₂); 3.65–3.75 (m, 2H, CH₂); 3.90 (s, 3H, OMe); 4.00–4.20 (m, 2H, CH₂); 4.53–4.69 (m, 1H, CH); 5.30–5.45 (m, 1H); 6.91 (d, *J* = 8.1 Hz, 1H); 7.05 (dd, *J* = 8.1 and 1.8 Hz, 1H); 7.09 (d, *J* = 1.8 Hz, 1H). ¹³C NMR (100.6 MHz, CDCl₃): δ 14.5 (q); 34.1 (t); 51.5 (t); 56.1 (q); 59.9 (d); 66.4 (t); 110.4 (d); 114.0 (d); 117.7 (d); 120.7 (d); 128.0 (s); 134.4 (s); 146.6 (s); 147.6 (s); 172.0 (s). HRMS: *m/z* calcd for C₁₅H₂₀NO₄ 278.1387, found 278.1387.

(*S,E*)-1-*tert*-Butoxycarbonyl-4-ethylidene-2-(trimethylsilyloxy-methyl)pyrrolidine (*E*-19). A 2 M solution of LDA in THF (0.25 mL, 0.5 mmol) was added to a solution of 5-(ethylsulfonyl)-1-phenyl-1*H*-tetrazole (119 mg, 0.5 mmol) in THF (4 mL) at -78 °C, and the mixture was stirred for 10 min. After this time, **18** (116 mg, 0.4 mmol) was added, and the mixture was stirred for an additional 30 min. The reaction mixture was quenched with satd NH₄Cl and extracted with CH₂Cl₂. The organic fractions were dried over MgSO₄ and filtered, and the solvent was removed under reduced pressure. Purification by silica gel column chromatography with hexane–EtOAc (97:3) yielded *Z/E*-19 (58 mg, 50%) in a 1:2 ratio as a colorless oil. IR (KBr film): ν 1702, 1397, 1251, 1109 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) (*E* diastereomer): δ 0.09 (s, 9H); 1.46 (s, 9H); 1.62 (d, *J* = 6.7 Hz, CH₃); 2.41–2.52 (m, 1H, CH₂); 2.54–2.66 (m, 1H, CH₂); 3.20–3.45 (m, 1H, CH₂); 3.55–3.65 (m, 1H, CH₂); 3.72–3.80 (m, 1H, CH₂); 3.87–4.05 (m,

2H); 5.32–5.42 (m, 1H, CH). ¹³C NMR (100.6 MHz, CDCl₃) (*E* diastereomer): δ -0.5 (q); 14.4 (q); 28.5 (q); 29.8 and 30.4 (t); 50.8 and 51.4 (t); 57.5 and 57.7 (d); 62.7 and 63.1 (t); 79.4 (s); 115.5 and 116.1 (d); 136.7 (s); 154.2 (s). HRMS: *m/z* calcd for C₁₅H₃₀NO₃Si 300.1989, found 300.1990.

(*S,E*)-4-Ethylidene-2-(hydroxymethyl)pyrrolidine (*E*-20). A solution of *Z/E*-19 in 1:2 ratio (95 mg, 0.31 mmol) in 10% TFA in CH₂Cl₂ (5 mL) was stirred at room temperature for 1 h. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography with CH₂Cl₂–MeOH (98:2 to 90:10) to obtain *Z/E*-20 in a 1:2 ratio in quantitative yield. IR (KBr film): ν 3380, 1677, 1435, 1135 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) (*E* diastereomer): δ 1.63 (d, *J* = 6.7 Hz, 3H, CH₃); 2.21–2.30 (m, 1H, CH₂); 2.58–2.68 (m, 1H, CH₂); 3.65–3.95 (m, 5H); 5.50–5.58 (m, 1H, CH). ¹³C NMR (100.6 MHz, CDCl₃) (*E* diastereomer): δ 14.7 (q); 28.2 (t); 48.7 (t); 60.8 (t); 61.6 (d); 120.6 (d); 130.9 (s). ¹H NMR (400 MHz, CD₃OD) (*E* diastereomer): δ 1.68 (d, *J* = 6.9 Hz, 3H, CH₃); 2.40 (dd, *J* = 16.4 and 8.4 Hz, 1H, CH₂); 2.75 (dd, *J* = 16.4 and 7.0 Hz, 1H, CH₂); 3.60–3.98 (m, 5H); 5.55–5.67 (m, 1H, CH). ¹³C NMR (100.6 MHz, CD₃OD) (*E* diastereomer): δ 14.8 (q); 29.1 (t); 50.1 (t); 61.2 (t); 62.7 (d); 121.0 (d); 133.1 (s). HRMS: *m/z* calcd for C₇H₁₄NO 128.1069, found 128.1070.

(*S,E*)-*N*-(4-Hydroxy-3-methoxybenzoyl)-4-ethylidene-2-(hydroxymethyl)pyrrolidine (*E*-16). PyBOP (93 mg, 0.18 mmol) was added to a solution of DIEA (64 μ L, 0.37 mmol) and vanillic acid (30 mg, 0.18 mmol) in THF (5 mL), and the mixture was stirred for 10 min. After this time, a solution of *Z/E*-20 in a 1:2 ratio (19 mg, 0.15 mmol) in THF was added, and the mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure, and the residue was dissolved in EtOAc and washed with satd NaHCO₃ and satd NH₄Cl. Purification by silica gel column chromatography with EtOAc yielded *Z/E*-16 (25 mg, 60%) in a 1:2 ratio. Purification by semipreparative HPLC using a Waters XBridge C18 column (10 \times 100 mm, 5 μ m), UV detection at 254 nm, with a flow of 3 mL/min, and H₂O–CH₃CN 18:82 as solvent system in isocratic conditions yielded *E*-16 (5.7 mg). The ¹H NMR and ¹³C NMR are identical as described for the natural product in Table 2 in the Supporting Information. $[\alpha]_D^{25} = -51.2$ (*c* 0.25, CH₂Cl₂). IR (KBr film): ν 3288, 1600, 1585, 1431, 1277, 1207 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.62 (d, *J* = 6.8, 3H, CH₃); 2.20–2.35 (m, 1H, CH₂); 2.67–2.77 (m, 1H, CH₂); 3.75 (bs, 2H, CH₂); 3.90 (s, 3H, OMe); 4.00–4.22 (m, 2H, CH₂); 4.67 (bs, 1H, CH); 5.34 (bs, 1H, CH); 6.91 (d, *J* = 7.8 Hz, 1H, Ar); 7.04 (d, *J* = 7.8, 1H, Ar); 7.09 (s, 1H, Ar). ¹³C NMR (100.6 MHz, CDCl₃): δ 14.5 (q); 30.1 (t); 55.1 (t); 56.3 (q); 60.6 (d); 67.1 (t); 110.6 (d); 114.1 (d); 117.6 (d); 121.0 (d); 128.3 (s) 134.7 (s); 146.7 (s); 147.8 (s); 172.0 (s). HRMS: *m/z* calcd for C₁₅H₂₀NO₄ 278.1387, found 278.1387.

Acknowledgment. This study was partially supported by CICYT (Grant No. CTQ 2009-07758), Generalitat de Catalunya, and the Barcelona Science Park. We express our thanks to Dr. F. Romero and Dr. R. Fernández Chimeno, leaders of our microbiological effort, for their excellent microbiological work. We thank to Mr. José Antonio Alonso García for helpful technical assistance.

Supporting Information Available: General procedures; tables of the bioactivity of isolated barmumycin and of its diacetyl derivative; NMR data Tables 2 and 3; ¹H and ¹³C NMR spectra of compounds **6a–e**, **7–14**, **17**, **18**, (*Z/E*)-**19**, and (*Z/E*)-**20**; and the ¹H and ¹³C NMR spectra with two-dimensional NMR experiments for compounds (*Z*)-**15**, (*Z*)-**1**, (*Z*)-**16**, and (*E*)-**16**. This information is available free of charge via the Internet at <http://pubs.acs.org>.